Abstract: Compounds of Formula (I), and pharmaceutically acceptable salts, esters, and prodrugs thereof: (I) are disclosed, wherein A, B, D, L, X, Y, Z and R2?, are described herein. The compounds exhibit antibacterial properties. The compounds of Formula (I) can be employed to treat or prevent bacterial infections as compounds per se or in the form of pharmaceutically acceptable salts, esters, or prodrugs. The compounds and their salts, esters, and prodrugs can also be employed as ingredients in pharmaceutical compositions, optionally in combination with other antibacterial agents, for the treatment of bacterial infections. Processes for making the compounds are also disclosed.

Abstract: Compounds described by the Formula (I): (I) or pharmaceutically acceptable salts, or N-oxides thereof. The compounds are useful for the treatment and prevention of protozoal diseases in mammals and birds. A method for controlling coccidiosis in poultry comprises administering an effective amount of the compound alone, or in combination with one or more anticoccidial agent(s). A composition for controlling coccidiosis in poultry comprises the compound alone, or in combination with one or more anticoccidial agent(s). Methods for the treatment and prevention of mammalian protozoal diseases, such as, for example, toxoplasmosis, malaria, African trypanosomiasis, Chagas disease, and opportunistic infections comprise administering the compound alone, or in combination with one or more antiprotozoal agent(s).

Abstract: Compounds of formula (I) and pharmaceutically acceptable salts thereof are useful in the treatment of cytokine mediated diseases such as arthritis and in the treatment and/or prevention of protozoal diseases such as coccidiosis

Abstract: Compounds of formula (I) and pharmaceutically acceptable salts thereof are useful in the treatment of cytokine mediated diseases such as arthritis and in the treatment and/or prevention of protozoal diseases such as coccidiosis.

Abstract: Inhibition of protein elongation factor 2 provides a target for identifying potential antifungal and antiparasitic compounds. EF2 inhibitors are useful as therapeutic agents against fungal and parasitic infections.

Abstract: Histone deacetylase inhibition provides a target for identifying potential antiprotozoal compounds. Histone deacetylase inhibitors are useful as therapeutic agents against protozoal infections.

Abstract: Histone deacetylase inhibition provides a target for identifying potential antiprotozoal compounds. Histone deacetylase inhibitors are useful as therapeutic agents against protozoal infections.

Abstract: Inhibition of protein elongation factor 2 provides a target for identifying potential antifungal and antiparasitic compounds. EF2 inhibitors are useful as therapeutic agents against fungal and parasitic infections.

Abstract: Histone deacetylase inhibition provides a target for identifying potential antiprotozoal compounds. Histone deacetylase inhibitors are useful as therapeutic agents against protozoal infections.

Abstract: The present invention provides novel cyclic tetrapeptides useful in the treatment or prevention of protozoal diseases; in particular, the novel compounds are active against the causative pathogens in malaria, toxoplasmosis, and coccidiosis. The invention also relates to the use of known compounds which are histone deacetylase inhibitors as antiprotozoal agents.

Abstract: A cyclohexapeptide base which is the nucleus of closely related antibiotics obtained by culturing Zalerion arboricola and its salts are described. They are useful intermediates for the preparation of new semisynthetic compounds having antimicrobial activity.

Abstract: An antibiotic agent produced by the cultivation of Zalerion arboricola which is a cyclic lipopeptide with very high activity against human pathogens and of very low mammalian toxicity is described. Its production and isolation are also described.

Abstract: A method for the treatment of Pneumocystis carinii, the causative agent of pneumonia of particular severity to immune compromised patients such as those with acquired immune deficiency syndrome (AIDS), by administering a lipophilic cyclohexapeptide compound of the general formula ##STR1## wherein the R groups are fully defined in the text, is described. Compositions suitable for the treatment of P. carinii are also disclosed.

Abstract: An antibiotic agent produced by the cultivation of Dictyochaeta simplex is described. The compound has broad antifungal activity and antipneumocystis activity.

Abstract: There is disclosed a new method for the treatment of Pneumocystis carinii, the causative agent of pneumonia of particular severity to immune-compromised patients such as those with acquired immune deficiency syndrome (AIDS). The method concerns the administration of a papulacandin compound.

Abstract: High levels of immunity are achieved in chickens inoculated intramuscularly or orally with E. acervulina extract immunogens. These extracts contain at least 20 polypeptides which induce a protective immune response not only against E. acervulina but also against E. tenella and E. maxima. The resulting immunity prevents intestinal lesions and reduces the number of viable oocysts in vaccinated and challenged birds. One or more of these polypeptides can be used as an immunogen to protect against coccidiosis.